PMID- 26799514
OWN - NLM
STAT- MEDLINE
DCOM- 20160926
LR  - 20160211
IS  - 1098-2264 (Electronic)
IS  - 1045-2257 (Linking)
VI  - 55
IP  - 4
DP  - 2016 Apr
TI  - NCOA2 is a candidate target gene of 8q gain associated with clinically aggressive 
      prostate cancer.
PG  - 365-74
LID - 10.1002/gcc.22340 [doi]
AB  - Prostate carcinomas harboring 8q gains are associated with poor clinical outcome, 
      but the target genes of this genomic alteration remain to be unveiled. In this 
      study, we aimed to identify potential 8q target genes associated with clinically 
      aggressive prostate cancer (PCa) using fluorescence in situ hybridization (FISH), 
      genome-wide mRNA expression, and protein expression analyses. Using FISH, we 
      first characterized the relative copy number of 8q (assessed with MYC flanking 
      probes) of a series of 50 radical prostatectomy specimens, with available global 
      gene expression data and typed for E26 transformation specific (ETS) 
      rearrangements, and then compared the gene expression profile of PCa subsets with 
      and without 8q24 gain using Significance Analysis of Microarrays. In the subset 
      of tumors with ERG fusion genes (ERG+), five genes were identified as 
      significantly overexpressed (false discovery rate [FDR], </= 5%) in tumors with 
      relative 8q24 gain, namely VN1R1, ZNF417, CDON, IKZF2, and NCOA2. Of these, only 
      NCOA2 is located in 8q (8q13.3), showing a statistically higher mRNA expression 
      in the subgroup with relative 8q gain, both in the ERG+ subgroup and in the whole 
      series (P = 0.000152 and P = 0.008, respectively). Combining all the cases with 
      NCOA2 overexpression, either at the mRNA or at the protein level, we identified a 
      group of tumors with NCOA2 copy-number increase, independently of ETS status and 
      relative 8q24 gain. Furthermore, for the first time, we detected a structural 
      rearrangement involving NCOA2 in PCa. These findings warrant further studies with 
      larger series to evaluate if NCOA2 relative copy-number gain presents prognostic 
      value independently of the well-established poor prognosis associated with MYC 
      relative copy-number gain.
CI  - (c) 2016 Wiley Periodicals, Inc.
FAU - Silva, Maria P
AU  - Silva MP
AD  - Department of Genetics, Portuguese Oncology Institute of Porto (IPO-Porto), 
      Porto, Portugal.
AD  - Cancer Genetics Group, IPO-Porto Research Center (CI-IPOP), Portuguese Oncology 
      Institute of Porto (IPO-Porto), Porto, Portugal.
FAU - Barros-Silva, Joao D
AU  - Barros-Silva JD
AD  - Department of Genetics, Portuguese Oncology Institute of Porto (IPO-Porto), 
      Porto, Portugal.
AD  - Cancer Genetics Group, IPO-Porto Research Center (CI-IPOP), Portuguese Oncology 
      Institute of Porto (IPO-Porto), Porto, Portugal.
FAU - Vieira, Joana
AU  - Vieira J
AD  - Department of Genetics, Portuguese Oncology Institute of Porto (IPO-Porto), 
      Porto, Portugal.
FAU - Lisboa, Susana
AU  - Lisboa S
AD  - Department of Genetics, Portuguese Oncology Institute of Porto (IPO-Porto), 
      Porto, Portugal.
FAU - Torres, Lurdes
AU  - Torres L
AD  - Department of Genetics, Portuguese Oncology Institute of Porto (IPO-Porto), 
      Porto, Portugal.
FAU - Correia, Cecilia
AU  - Correia C
AD  - Department of Genetics, Portuguese Oncology Institute of Porto (IPO-Porto), 
      Porto, Portugal.
AD  - Cancer Genetics Group, IPO-Porto Research Center (CI-IPOP), Portuguese Oncology 
      Institute of Porto (IPO-Porto), Porto, Portugal.
FAU - Vieira-Coimbra, Marcia
AU  - Vieira-Coimbra M
AD  - Cancer Biology and Epigenetics Group, IPO-Porto Research Center (CI-IPOP), 
      Portuguese Oncology Institute of Porto (IPO-Porto), Porto, Portugal.
FAU - Martins, Ana T
AU  - Martins AT
AD  - Cancer Biology and Epigenetics Group, IPO-Porto Research Center (CI-IPOP), 
      Portuguese Oncology Institute of Porto (IPO-Porto), Porto, Portugal.
AD  - Department of Pathology, Portuguese Oncology Institute of Porto (IPO-Porto), 
      Porto, Portugal.
FAU - Jeronimo, Carmen
AU  - Jeronimo C
AD  - Cancer Biology and Epigenetics Group, IPO-Porto Research Center (CI-IPOP), 
      Portuguese Oncology Institute of Porto (IPO-Porto), Porto, Portugal.
AD  - Department of Pathology and Molecular Immunology, Institute of Biomedical 
      Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal.
FAU - Henrique, Rui
AU  - Henrique R
AD  - Cancer Biology and Epigenetics Group, IPO-Porto Research Center (CI-IPOP), 
      Portuguese Oncology Institute of Porto (IPO-Porto), Porto, Portugal.
AD  - Department of Pathology, Portuguese Oncology Institute of Porto (IPO-Porto), 
      Porto, Portugal.
AD  - Department of Pathology and Molecular Immunology, Institute of Biomedical 
      Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal.
FAU - Paulo, Paula
AU  - Paulo P
AD  - Department of Genetics, Portuguese Oncology Institute of Porto (IPO-Porto), 
      Porto, Portugal.
AD  - Cancer Genetics Group, IPO-Porto Research Center (CI-IPOP), Portuguese Oncology 
      Institute of Porto (IPO-Porto), Porto, Portugal.
FAU - Teixeira, Manuel R
AU  - Teixeira MR
AD  - Department of Genetics, Portuguese Oncology Institute of Porto (IPO-Porto), 
      Porto, Portugal.
AD  - Cancer Genetics Group, IPO-Porto Research Center (CI-IPOP), Portuguese Oncology 
      Institute of Porto (IPO-Porto), Porto, Portugal.
AD  - Department of Pathology and Molecular Immunology, Institute of Biomedical 
      Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160122
PL  - United States
TA  - Genes Chromosomes Cancer
JT  - Genes, chromosomes & cancer
JID - 9007329
RN  - 0 (NCOA2 protein, human)
RN  - 0 (Nuclear Receptor Coactivator 2)
SB  - IM
MH  - *Chromosome Duplication
MH  - *Chromosomes, Human, Pair 8
MH  - Gene Expression Profiling
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Nuclear Receptor Coactivator 2/*genetics
MH  - Prognosis
MH  - Prostatic Neoplasms/*genetics/physiopathology
EDAT- 2016/01/23 06:00
MHDA- 2016/09/27 06:00
CRDT- 2016/01/23 06:00
PHST- 2015/10/01 00:00 [received]
PHST- 2015/11/16 00:00 [revised]
PHST- 2015/11/30 00:00 [accepted]
PHST- 2016/01/23 06:00 [entrez]
PHST- 2016/01/23 06:00 [pubmed]
PHST- 2016/09/27 06:00 [medline]
AID - 10.1002/gcc.22340 [doi]
PST - ppublish
SO  - Genes Chromosomes Cancer. 2016 Apr;55(4):365-74. doi: 10.1002/gcc.22340. Epub 
      2016 Jan 22.